- Conditions
- Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
- Interventions
- HTS 3%, Standard fluid management
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 31
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bleeding Complications
- Interventions
- Clopidogrel, Prasugrel, Tricagrelor
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Pancreatitis, Diabetes Mellitus
- Interventions
- Closed Loop Insulin
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Atrial Fibrillation
- Interventions
- AMIODARONE
- Drug
- Lead sponsor
- Kevin W Hatton, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Bone Metastases
- Interventions
- Bone Scan: F18-Fluoride PET/CT or TC-MDP
- Device
- Lead sponsor
- American College of Radiology - Image Metrix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Freemont, California • Los Angeles, California + 9 more
- Conditions
- Urothelial Cancer, Urinary Bladder Neoplasms
- Interventions
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 16 more
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 178
- States / cities
- Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 114 more
- Conditions
- Coronary Artery Disease
- Interventions
- Image Quality, Diagnostic Accuracy
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more
- Conditions
- Type I Diabetes
- Interventions
- Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
- Biological
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Prostatic Neoplasms, Prostate Cancer
- Interventions
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ischemic Heart Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Radiotherapy
- Interventions
- Conventional Bolus, 3D Printed Bolus
- Device
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant, A.3 Lucinactant, A.4 Lucinactant, B.1 Lucinactant, B.2 Lucinactant
- Drug · Other
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Warrington, Pennsylvania
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Erlotinib, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer, Thyroid Cancer
- Interventions
- Definity, Acoustic Angiography
- Drug · Device
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Uterine Atony, Hypotension
- Interventions
- Oxytocin Infusion, Oxytocin Bolus
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Faster Insulin Aspart (Fiasp®)
- Drug
- Lead sponsor
- Mountain Diabetes and Endocrine Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Asheville, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- rhPSMA-7.3 (18F)
- Drug
- Lead sponsor
- MidLantic Urology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Bala-Cynwyd, Pennsylvania
- Conditions
- Metastatic Prostate Cancer
- Interventions
- 18F-DCFBC
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Renal Cancer, Kidney Cancer
- Interventions
- Ultrasound with intravenous microbubble contrast injection
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Knee Osteoarthritis
- Interventions
- Femoral Nerve Catheters, Single Shot Femoral Nerve Blocks
- Drug
- Lead sponsor
- Eastern Maine Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Bangor, Maine
- Conditions
- Anesthesia
- Interventions
- MTPI, Classic Induction
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas